Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Medivir AB is a Swedish pharmaceutical company focused on developing innovative treatment solutions for patients in need of improved therapeutic options. The company primarily specializes in the research and development of transformative antiviral and oncology medications. Medivir's pipeline includes a diverse array of projects aimed at addressing unmet medical needs through highly targeted therapies. The organization leverages advanced technology and scientific expertise to develop both proprietary and partnered projects that advance its strategic objectives. Medivir AB plays a critical role in the health sector by contributing to the eradication and management of challenging diseases, particularly in the areas of virology and cancer treatment. Positioned within the pharmaceutical industry, Medivir represents a unique blend of innovation and clinical excellence, underpinned by strong research capabilities and strategic collaborations. As a public entity, Medivir AB is significant to the financial market and healthcare industry for its commitment to advancing medicine and improving patient outcomes globally.
kr 0.11
kr 0.00 (-2.84%)
Live · 10:49 PM · Twelve Data
The business is unprofitable at the operating level (-1092.98% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 144.1% YoY with margins expanding 2583.0pp.
Negative free cash flow of -kr 73M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 9M
▲ +144.1% YoY
Net Income (TTM)
-kr 91M
▲ +23.4% YoY
Op. Margin
-1006.74%
▲ +2583.0pp YoY
ROIC
-50.62%
▲ +5.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 60M
▲ +40.9% YoY
Op. Cash Flow (TTM)
-kr 56M
▲ +40.9% YoY
Net Debt
-kr 111M
Net Cash Position
Cash & Equiv.
kr 119M
3Y CAGR: +24.5%
Continue Research
Medivir AB (MVIR.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Medivir AB scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Medivir AB scores 40 out of 100 on Intrinsiqq's quality score, passing 3 of 6 checks, which makes it a mixed business on these measures. Recent fundamentals include a -1,006.7% operating margin and a -50.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh MVIR.XSTO's valuation and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.